« Back to Directory of Resources
Treatments Under Development
Here you will find a list of current treatments under development:
| Brand Name: | |
| Generic Name: | defibrotide |
| Code Name: | |
| Company: | Gentium SpA |
| FDA Clinical Phase: | 1/2 |
Description:
Defibrotide is an anticoagulant (a drug that prevents blood clotting) that may make myeloma cells more susceptible to chemotherapy. It is not an anti-tumor drug and…
| Brand Name: | |
| Generic Name: | |
| Code Name: | BI-505 |
| Company: | BioInvent |
| FDA Clinical Phase: | 1 |
Description:
BI-505 is a fully human antibody that causes cell death. It binds to the protein ICAM-1 (CD54), which is more common in tumors than in normal tissue.…
| Brand Name: | |
| Generic Name: | dacetuzumab |
| Code Name: | SGN-40 |
| Company: | Seattle Genetics Inc. |
| FDA Clinical Phase: | 1 |
Description
Dacetuzumab is a monoclonal antibody that specifically binds to and works against a molecule called a CD40 receptor, which appears in abnormally high amounts in…
| Brand Name: | |
| Generic Name: | |
| Code Name: | BT-062 |
| Company: | Biotest |
| FDA Clinical Phase: | 1/2 |
Description:
BT-062 (news articles) is a toxic drug bound to an antibody that helps deliver the treatment to myeloma and other cancer cells. When the compound…
| Brand Name: | |
| Generic Name: | milatuzumab |
| Code Name: | |
| Company: | Immunomedics, Inc. |
| FDA Clinical Phase: | 1/2 |
Description:
Milatuzumab is a humanized monoclonal antibody that targets tumors expressing the CD74 antigen. As the first anti-CD74 antibody studied in human clinical trials,…
| Brand Name: | |
| Generic Name: | |
| Code Name: | AT9283 |
| Company: | Astex |
| FDA Clinical Phase: | 2 |
Description:
AT9283 is a kinase inhibitor that prevents cell division, thereby stopping the growth of cancer cells. Several Phase 1 clinical trials have shown that AT9283 is safe…
